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Abstract
Background: Diagnosing D-Dimer early is essential to optimize clinical treatment and
quality of life and reduce mortality. This study aims to identify the difference of D-
Dimer levels (ng/ml) in patients with stroke within the 6- and 24-h period compared
to patients that mimic stroke.
Methods: An electronic database search across PubMed/MEDLINE, Cochrane, Web
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of Science, CINAHL, EMBASE, and Scopus was conducted until December 10, 2021.
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mimics or controls reporting D-Dimer values. Quality assessment was conducted
using GRADE. The standardized mean difference and 95% confidence intervals were
calculated in addition to the difference of means in the crude form. Heterogeneity
was assessed using Cochran's Q statistic and the I2 index. A random-effects model
was used. The statistical analysis was conducted using RevMan 5.4.
Results: Out of 2901, there were 318 (11%) participants from upper-middle-income
countries, whereas the others were from high-income countries. Large positive effect size was found for D-Dimer in the stroke group (Cohen's d = 2.82 [1.73–3.9];
p < 0.00001), meaning that those with stroke had higher D-Dimer values on presentation compared to the stroke mimics/controls. A large difference in means was found
in the two groups (MD = 685.1 [324.2, 1045.99]; p < 0.00001), suggesting that there
was a significantly higher laboratory value in the stroke group.
Conclusion: Our findings must be used in caution as the most reliable diagnostic tests
for stroke are CT and MRI. Laboratory testing such as D-Dimer values is a valuable
clinical adjuvant in diagnosing total stroke.
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2.1 | Inclusion and exclusion criteria

In 1970, the World Health Organization (WHO) defined stroke as

The following study types were included: Controlled/randomized

“rapidly developing clinical signs of global or focal disturbance in the

clinical trials, retrospective or prospective cohorts, case-controlled

cerebral function that lasting more than 24 h or leading to death with

studies with five or more patients. The studies employed adult pa-

no notable cause other than of vascular origin”.1 While this definition

tients aged 18 or above with no gender predilections. Studies that re-

is used across the world, the WHO definition relies heavily on clin-

ported laboratory values of patients with stroke compared to stroke

ical symptoms. It is currently considered outdated by the American

mimics/controls were included. All other studies were excluded.

Stroke Association and the American Heart Association due to advances in the nature, timing, and clinical recognition of stroke and its
mimics, in addition to the progressing imaging findings that require

2.2 | Search strategy

an updated definition. 2,3 The global prevalence of stroke in 2019
was reported at 101.5 million individuals, whereas ischemic stroke
4

was reported in 77.2 million people. Overall, the age-standardized

We used a systematic search strategy to assess electronic databases
as per the PRISMA checklist (Figure 1). The PRISMA checklist and

stroke prevalence was highest in Southeast Asia, the Middle East,

protocol are attached in Appendices S1 and S2. The search was con-

East Asia, and Oceania.4 In 2019, 6.6 million deaths occurred due to

ducted from inception until December 10, 2021. There were no lan-

cerebrovascular disease worldwide.4 Further, ischemic stroke rose

guage restrictions meaning that non-English studies were translated

from 13th to 8th leading cause of global YLL (years of life lost be-

to English. PubMed/MEDLINE, Cochrane, Web of Science, CINAHL,

cause of premature mortality) between 1990 and 2019.4

EMBASE, and Scopus were searched. We manually searched SAGE,

Hemostasis is the property of circulation where blood retains

Elsevier, Science Direct, and Google Scholar to ensure no studies

fluidity within the vasculature, whereas the system simultaneously

were missing. The reference lists of all screened were also searched

prevents excessive blood loss upon injury.5 When the vascular in-

(umbrella methodology). The search terms across the databases

jury occurs, clotting reactions are initiated, creating an insoluble

comprised the following using the BOOLEAN (and/or) logic: D-

fibrin-platelet plug at the site of the vessel wall defect, arresting

Dimer, Laboratory, Stroke, Ischemic, Hemorrhagic, Trial, and Cohort.

blood loss, and finally restoring the vascular integrity.6 The acti-

The titles and abstracts of the screened studies were reviewed and

vation releases many substances required in platelet aggregation

screened independently by all reviewers. Any disagreements were

and initiates the coagulation cascade, leading to the formation of

resolved by active discussion. Cohen's coefficient of the agreement

cross-linked fibrin, creating a clot at the injury site. During the fibri-

was computed to quantify the inter-reviewer agreement.

nolysis process, plasmin cleaves fibrinogen and soluble fibrin. The
smallest oligomer is D-dimer.7 On laboratory testing, the D-Dimer
levels reflect the intravascular levels of fibrin turnover, confirming

2.3 | Statistical analysis

the plasmin and thrombin generation that has occurred.6 When considering clinical practice, abnormal elevation of D-Dimer indicates

The studies were stored in a bibliography management software

disseminated intravascular clotting, whereas low levels aid in ruling

named Endnote X9 (Clarivate Analytics). The deduplication fea-

out thromboembolic events such as pulmonary embolism and deep

ture was applied using the software when screening the studies.

venous thrombosis.8,9 While D-Dimer levels have been known to be

We sought to meta-analyze the means and standard deviations of

associated with long-term mortality in the population, few studies

D-Dimer, applying a random-effects model. These variables were

assess the D-Dimer levels and stroke incidence.10

continuous, and the difference in means using 95% confidence in-

This study aims to identify the D-Dimer levels (ng/ml) in patients

tervals was computed. Moreover, the standardized mean difference

with stroke within the 6- and 24-h period compared to patients that

that was reported as Cohen's d with the 95% confidence interval

mimic stroke. In this area, we conduct a meta-analysis to system-

was plotted and reported in the results. A funnel plot was utilized

atically analyze the correlation between D-dimer levels and stroke

to test for publication bias, where we ascertained the heterogeneity

incidence.

between the included studies. The heterogeneity between the included studies was tested using the χ2-based Q test and the I2 index.

2
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A sensitivity analysis was additionally taken by removing the studies with the larges effect size and re-calculating results. The statistical analysis was conducted using Review Manager 5.4 (RevMan,

In accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA Statement 2020), clinical tri-

Cochrane).
The GRADE (Grading of Recommendations, Assessment,

als, observational studies, and case-controlled studies (five or more

Development, and Evaluations) framework was deployed to sum-

patients) with a stroke group and a stroke mimic/control group that

marize the quality of evidence by providing a systematic approach

reported D-Dimer values within the 24-h period were included.

for making clinical practice recommendations. The GRADE certainty

|
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F I G U R E 1 PRISMA flowchart

ratings were tabulated to indicate the quality of evidence across the

(N = 1876) and stroke mimics/control group (N = 468). Large posi-

included studies.

tive effect size was found for D-Dimer in the stroke group (Cohen's
d = 2.82, 95% CI = 1.73, 3.9, p < 0.00001), meaning that stroke pa-

3
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tients had higher D-Dimer values on presentation compared to the
stroke mimics/controls (Figure 2).
The mean difference (MD), being a standard statistic, measures

The overall Kappa score calculated for the inter-reviewer agreement

the absolute difference between the mean D-Dimer value in the

was 0.92. In total, 3315 studies were identified from databases,

two groups. Nine of the 11 studies reported D-Dimer values in the

of which 512 duplicates were removed. The title and abstracts of

two groups. A large difference in means was found in both groups

2803 studies were screened, with 1862 studies not retrieved as

(MD = 685.1, 95% CI = 324.2, 1045.99, p < 0.00001), meaning that

they did not fit the inclusion criteria. Finally, on full-text reviewing

there was a significantly higher laboratory value in the stroke group

of the 1862 studies, 84 studies were reviewed in depth. Of those,

(Figure 3).

1778 studies were excluded as they met the exclusion criteria, and

An analysis was conducted to note the specific changes at 24 h

11 studies were included in the final synthesis (Figure 1). The char-

compared to those within 6 h, by noting Cohen's d effect of D-Dimer

acteristics of included studies are listed in Table 1.

values. In the first subgroup analysis of D-Dimer values within the

Cohen's d effect allows us to assess the direction of effect. In this

6-h time frame, a medium effect size was noted D-Dimer in the

meta-analysis, a positive effect size (i.e., Cohen's d) indicates that the

stroke group (Cohen's d = 0.49, 95% CI = 0.29, 0.69, p < 0.0001)

effect (i.e., Stroke presentation within the 24-h testing period using

(Figure 4). In the second subgroup analysis of D-Dimer values at the

D-Dimer laboratory values) increases the mean. The interpretation

24-h time-frame, a larger positive effect size was noted for D-Dimer

we refer to for effect sizes includes small (d = 0.2), medium (d = 0.5),

in the stroke group compared to within the 6-h time period (Cohen's

and large (d = 0.8) based on benchmarks suggested by Cohen (1988).

d = 4.19, 95% CI = 1.77, 6.61, p = 0.0007) (Figure 4). The findings

Nine of the 11 studies reported D-Dimer values in the stroke group

suggest that D-Dimer laboratory values had a medium effect size

4 of 10
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TA B L E 1 Characteristics of included studies

No.

Author, year

1

Bustamante et al., 201711

2

3

4

5

6

7

8

9

n, N

D-Dimer value (ng/ml)

Patients with Stroke

463/541

6751.5 (1033.7)

Patients Mimicking Stroke/
Controls

78/541

6235.9 (1027.2)

Knauer et al., 201212
Patients with Stroke

100/149

Median = 675

Patients Mimicking Stroke/
Controls

49/149

Median = 322

Patients with Stroke

337

IS = 1068.3 (1192.3);
HS = 1099.2
(1383.6)

Patients Mimicking Stroke/
Controls

NR

NR

Patients with Stroke

915/1005

1048.1 (1188)

Patients Mimicking Stroke/
Controls

90/1005

722 (904.1)

Patients with Stroke

152/1005

322.57 (60.34)

Patients Mimicking Stroke/
Controls

46/1005

305.76 (49.52)

Patients with Stroke

HS = 29/120;
IS = 71/120

HS = 1780 (3298.5);
IS = 5741 (194.1)

Patients Mimicking Stroke/
Controls

20/120

150 (31.85)

Montaner et al., 201213

Mean age (years)

Study design

Country

71.95 ± 15.6

Prospective,
cohort

Spain

71.26 ± 15.8 and
50 ± 14.2

Prospective,
cohort

Germany

71.7 ± 12.25

Montaner et al., 2011a14

Meng et al., 201115

Kavalci et al., 201116

Glickman et al., 201117
Patients with Stroke

34/63

2400 (1500)

Patients Mimicking Stroke/
Controls

29/63

1000 (1300)

Kim et al., 201018
Patients with Stroke

89/146

888.1 (1289)

Patients Mimicking Stroke/
Controls

57/146

188.6 (113.8)

Patients with Stroke

86/149

1740 (130)

Patients Mimicking Stroke/
Controls

63/149

530 (140)

Ageno et al., 200219

Spain

72.63 ± 12.46 and
69.57 ± 17.13

Prospective,
cohort

Spain

58.72 ± 8.32 and
51.89 ± 7.04

Prospective,
cohort

China

72 ± 12

Prospective,
cohort

Turkey

65.2 ± 16.2 and
50.9 ± 19.1

Prospective,
cohort

USA

66.6 ± 11.8 and
43.8 ± 12

Prospective,
cohort

Korea

75.7 and 75.4

Prospective,
cohort

Italy

|
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Different
conditions
demarcated

Time of sample
collection

Methodology used

Diagnostic criteria

IS, ICH, SM

Within 6 h

Immunoassays

Stroke diagnosis was performed by trained neurologists according
to the World Health Organization definition and confirmed by
neuroimaging. Stroke mimic (control) diagnosis was supported
with the ancillary tests deemed to be necessary in each case
(i.e., EEG, lumbar puncture)

15 months

IS, SM, TIA

Within 6 h

Sandwich Fluorescence
Immunoassay
Technology

Clinical investigation and collection of blood samples were
performed immediately after admission. This procedure was
directly followed by a typical standard MRI-based stroke
imaging protocol
(DWI, T2*w, TOF-MRA, FLAIR, T2w, T1w, PWI)

5 months

IS, ICH

Within 24 h

ELISA

Diagnosis was made by a brain CT scan and other serial blood tests

2 years

IS, ICH, SM

Within 24 h

Sandwich ELISA

Electrocardiography, chest radiography, carotid ultrasonography,
complete blood count, and leukocyte differential and blood
biochemistry were performed in all patients; when indicated
some patients also underwent special coagulation tests,
transthoracic echocardiography, brain magnetic resonance
imaging, electroencephalography, and Holter monitoring.
Previously defined etiological subgroups were determined using
the Trial of Org10172 in Acute Stroke Treatment criteria. Stroke
was also classified according to the Oxfordshire Community
Stroke Project criteria, based on clinical symptoms, location
and extent of cerebral infarction. All patients underwent brain
computed tomography that was reviewed by a neuroradiologist
with extensive experience in acute stroke

2 years

IS, SM

Within 4.5 h

Immuno-turbidimetry
assay

Symptomatic for over 1 h (s limb numbness or weakness,
dyskinesia, dysphasia, balance disturbance, diplopia, dizziness/
vertigo/coordination, speech/language confusion, decreased
level of consciousness, headache, visual changes, and other
local neurological symptoms), brain imaging findings (MRI/
DWI/MRA or CTA within 24–72 h of the event)

NR

IS, ICH, HC

Within 24 h

Triage Stroke Panel

Neuroimaging testing according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria

2 years

IS, SM

Within 24 h

Specific Immunoassays

Final diagnosis of stroke was rendered by review of all clinical,
imaging, and conventional laboratory data during admission

NR

IS, ICH

Within 6 h

Triage Stroke Panel

Diagnosis was made with MRI and supported by clinical signs and
symptoms of focal neurologic signs/symptoms of vascular
origin, with biomarker analysis

5 months

IS, TIA, HC

Within 24 h

STA Latest D-dimer
assay

Computed tomographic scan of the brain and stroke subtypes
defined as per the Baltimore-Washington Cooperative Young
Study and the Oxfordshire Community Stroke Project

16 months

Length of
follow-up

6 of 10
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TA B L E 1 (Continued)

No.
10

11

Author, year

n, N

D-Dimer value (ng/ml)

Patients with Stroke

86/146

894 (1.436)

Patients Mimicking Stroke/
Controls

60/146

220 (133)

20

Altès et al., 1995

Takano et al., 199021
Patients with Stroke

22/47

528.7 (94.9)

Patients Mimicking Stroke/
Controls

25/47

80.2 (8.4)

Mean age (years)

Study design

Country

64 ± 10.5 and 59 ± 4.3

Prospective,
cohort

Spain

64.7 and 61

Prospective,
cohort

Japan

Abbreviations: ICH, intracerebral hemorrhage; IS, ischemic stroke; NR, not reported; SM, stroke mimics; TIA, transient ischemic attack.

F I G U R E 2 Forest plot of D-Dimer ng/ml (mean values [SD]) Stroke versus Stroke Mimics/Controls. SMD = 2.82 [95% CI = 1.73, 3.90];
Heterogeneity: Tau2 = 2.61; Chi2 = 516.75, df = 8 (p < 0.00001); I2 = 98%; Test for overall effect: Z = 5.09 (p < 0.00001)

F I G U R E 3 Forest plot of D-Dimer ng/ml (mean values [SD]) Stroke versus Stroke Mimics/Controls. MD = 685.1 [95% CI =324.20,
1045.99]; Heterogeneity: Tau2 = 269120.20; Chi2 = 3221.30, df = 8 (p < 0.00001); I2 = 100%; Test for overall effect: Z = 3.72 (p = 0.0002)
within the 6-h period making them a useful predictor of stroke, and

values in the stroke group had a very large effect size but with the

that within the 24-h period, there were large effect size associations

lack of significance. On the other hand, the non-ELISA techniques

to the laboratory indicator.
Another subgroup analysis was conducted to note the differ-

had a large effect size with significant findings in the stroke group of
D-Dimer laboratory values.

ences between ELISA and other techniques. While a large effect

Large heterogeneity was found in the included studies, owing

size was found for the ELISA technique the results were insignifi-

to the different nature under which they were conducted. A funnel

cant (Cohen's d = 4.95, 95% CI = −0.86, 10.76, p = 0.09) (Figure 5).

plot was created to visually inspect publication bias, as depicted

On sub-analyzing the other techniques, the following results were

in Figure 6. We found three studies deviating from an inverted

yielded: Cohen's d = 0.56, 95% CI = 0.36, 0.76, p < 0.00001)

funnel shape, with the other six being within a reasonable bound

(Figure 5). Overall, the results for ELISA technique and D-Dimer

(Figure 6).

|
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Different
conditions
demarcated

Time of sample
collection

Methodology used

Diagnostic criteria

Length of
follow-up

IS, HC

Within 24 h

ELISA

Diagnosis was confirmed in all cases by CT or MRI testing

8 months

IS, HC

Within 24 h

ELISA

Stroke was confirmed with electrocardiography. Brain CT and
cerebral angiography were performed to confirm findings

NR

F I G U R E 4 Subgroup analysis of D-Dimer ng/ml (mean values [SD]) Stroke Versus Stroke Mimics/Controls within 6 h [SMD = 0.49 [95%
CI = 0.29, 0.69]; Heterogeneity: Tau2 = 0.01; Chi2 = 2.73, df = 2 (p = 0.26); I2 = 27%; Test for overall effect: Z = 4.76 (p < 0.00001)] (top)
versus at 24 h [SMD = 4.19 [95% CI = 1.77, 6.61]; Heterogeneity: Tau2 = 8.94; Chi2 = 497.86, df = 5 (p < 0.00001); I2 = 99%; Test for overall
effect: Z = 3.39 (p = 0.0007)] (bottom)
A sensitivity analysis was performed for D-Dimer outcomes

The GRADE approach was used to assess the quality of D-Dimer

applying the entire patient population for D-Dimer and SMD out-

evidence for stroke detection across the 11 studies. Overall, eight

comes. As noted in Figure 2, the studies with the highest weight were

studies had moderate GRADE certainty ratings, with two being high

Montaner et al. (2011a), Bustamante et al. (2017), Meng et al. (2011),

and one low. The evidence presented in this meta-analysis is of mod-

and Kim et al. (2010). The studies were removed from the analy-

erate quality. Hence, our findings must be used with caution and

sis to recompute findings. On removing Montaner similar findings

informed clinical application.

were obtained (Cohen's d = 3.21 [95% CI = 1.82, 4.59] p < 0.00001).
Similarly, on removing both Montaner and Bustamante, the findings
were comparable (Cohen's d = 3.66 [95% CI = 1.8, 5.52], p = 0.0001).

4
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DISCUSSION

Then, on removing both Meng and Kim, the results were similar to the original findings (Cohen's d = 3.59, 95% CI = 2.03–5.14,

Studies in the past have explored the role of D-Dimer as a helpful

p < 0.00001). The sensitivity analysis was conducted to repeat the

indicator in evaluating stroke patients. These studies had reported

primary analysis (SMD and D-Dimer values across all included stud-

that patients with the various strokes and stroke-related diseases

ies); however, the moderate publication bias was arbitrary and could

have acutely increased plasma D-Dimer levels.6 Literature also sup-

not be connected to the four studies with the highest weight.

ports the clinical utility of D-Dimer, a product of fibrin degradation,

The “Grading of Recommendations, Assessment, Development,

in the early diagnosis of stroke subtypes, in clinical practice as an

and Evaluations” (GRADE) certainty scores are enlisted in Table 2.

extension to patients with acute cerebrovascular ischemic events.19

8 of 10
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F I G U R E 5 Subgroup analysis of D-Dimer ng/ml (mean values [SD]) Stroke Versus Stroke Mimics/Controls comparing ELISA [SMD = 4.95
[95% CI = −0.86, 10.76]; Heterogeneity: Tau2 = 26.08; Chi2 = 282.65, df = 2 (p < 0.00001); I2 = 99%; Test for overall effect: Z = 1.67
(p = 0.09)] (top) to all other techniques [SMD = 0.56 [95% CI = 0.36, 0.76] Heterogeneity: Tau2 = 0.02; Chi2 = 5.83, df = 4 (p = 0.21);
I2 = 31%; Test for overall effect: Z = 5.53 (p < 0.00001)] (bottom)
F I G U R E 6 Funnel plot for the visual
inspection of publication bias

While other markers such as copeptin, s100B, GFAP are also im-

wherein stroke patients had higher D-Dimer values on presentation

portant in acute stroke, D-Dimer is considered one of the strong-

compared to the stroke mimics/controls. The majority of the studies

est markers of intravascular protein degradation, ascribed to the

were conducted within a 24-h period, while three were completed

action of factor IIa, issue XIIIa, and fibrinolysin. In clinical practice,

within a 6-h timeframe, with only one done in the 4.5-h period.

abnormal D-Dimer plasma levels are used as important predictors

While several observational studies report associations between

of disseminated intravascular clotting, and low levels are often used

D-Dimer levels and the incidence of stroke, the findings have been

to rule out critical events such as pulmonary embolism and deep ve-

inconsistent so far. 23–25 Yuan and colleagues analyzed the associa-

nous thrombosis.

22

Very few studies assess the role of D-Dimer with

the risk of stroke of adverse clinical outcomes post-stroke.
This meta-analysis finds that patients with stroke compared to

tions between D-Dimer and the risk of stroke (i.e., pre-stroke) employing a sample set of 22,590 patients. 22 The authors found that
the D-Dimer levels increased the risk of total stroke by 40% (RR =

stroke mimics yielded a mean difference of 685.1 (95% CI = 324.20,

1.4, 95% CI = 1.2–1.63). 22 In our study, we found a large positive

1045.99); patients with stroke had a higher laboratory value of D-

effect size of D-Dimer levels among patients who were diagnosed

Dimer on testing. Moreover, a large positive effect size was found

with stroke using laboratory testing as an adjuvant to imaging find-

for D-Dimer in the stroke group (d = 2.82, 95% CI = 1.73, 3.9),

ings (Cohen's d = 2.82, 95% CI = 1.73–3.9). Yuan et al. also noted that

|
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when the D-Dimer level increased by 50 ng/ml, the risk of stroke

classification.31 We posit that without the implementation of pri-

increased by 0.3%. 22

mary prevention strategies and cheap “filtering” tests available at

The two imaging tests allow a clear view of the head, including

primary care centers, the stroke burden will continue to rise across

the blood vessels and tissue, including computed tomography (CT),

the world, particularly in low- and middle-income countries. In our

scans, and magnetic resonance imaging (MRI). The average cost of

meta-analysis, only two upper-middle-income countries were repre-

a CT scan in the United States is $3275 ($300–$6750), compared

sented, whereas the other nine were HIC (Figure 7).

to around $80 ($40–$250) in Pakistan. 26,27 The price of an MRI in
the United States is $1325 ($375–$2850), whereas, in Pakistan, the
reported price is around $10 ($4–$ 45). 26,27 In the United States,
the average D-Dimer test cost ranges between $239 and $303,

4.1 | Strengths and limitations

28

whereas in Pakistan, it costs around $8–$14 for the test. 29 While

The findings from this meta-analytical study can help guide evidence-

Pakistan and the United States have been used as case studies to

based healthcare planning and resource allocation for stroke across

review test prices in LMIC and HIC, respectively, it is essential to

LMIC and HIC by prioritizing measures to diagnose it within the 6-h

note that access to CT and MR scanners is a critical prerogative. For

period. The findings from this meta-analysis have summarized the

instance, urban centers in LMIC are known to have a large propor-

results of D-Dimer among patients that have confirmed stroke and

tion of CT and MRI scanners, whereas rural centers may have limited

compared it to stroke mimics in a comprehensive manner. To ensure

access to facilities.30

the best quality evidence, we computed mean differences and SMD

The annual number of deaths due to strokes increased substan-

to ensure that we do not synthesize the risk estimates only, stabi-

tially from 1990 to 2019, despite the reductions in age-standardized

lizing our results. These findings provide a state-of-the-art under-

rates, specifically in the 70 and above age group. The highest num-

standing of how D-Dimer may be applicable across LMIC in primary

ber of age-standardized stroke-related mortality and DALY rates

care centers and in diagnosing stroke.

belonged to the low-income countries as per the World Bank

There are certain limitations in this meta-analysis. First, we could
not differentiate results based on the different stroke types because

TA B L E 2 GRADE certainty rating of all included studies
Author, year

GRADE certainty ratings

Bustamante et al., 201711

High

Knauer et al., 201212

Moderate

Montaner et al., 201213

Moderate

Montaner et al., 2011a14

Moderate

Meng et al., 201115

Moderate

Kavalci et al., 201116

Low
17

Glickman et al., 2011

High

Kim et al., 201018

Moderate
19

Ageno et al., 2002

Moderate

20

Altès et al., 1995

Moderate

Takano et al., 199021

Moderate

F I G U R E 7 The countries represented
in this meta-analysis. In total, 318 out
of 2901 participants were from upper-
middle-income countries (11%; China
and Turkey). The majority of participants
(N = 2583) were from high-income
countries (89%, Spain, Germany, USA,
Korea, Italy, Japan)

of the paucity of data. Second, the number of included studies was
limited due to the lack of reported data from LMIC. Third, we could
not account for confounding factors as the study populations were
not demarcated in the included studies. Finally, racial data were
not aligned to the clinical outcomes; hence, a racial-specific meta-
analysis could not be undertaken.
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CO N C LU S I O N

Based on our study discoveries, high D-Dimer levels are strongly correlated to a stroke diagnosis. There is no evidence for the different stroke
types, and our clinical applications are limited to total stroke incidences.
The quantification of D-Dimer levels across the different stroke subtypes and TIA must be substantiated to corroborate our findings.
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